Expression of Met Receptor Fragments in Non Small Cell Lung Cancer
Conditions
Non Small Cell Lung Cancer
Conditions: official terms
Carcinoma, Non-Small-Cell Lung - Lung Neoplasms
Conditions: Keywords
non small cell lung cancer, Met fragments
Study Type
Interventional
Study Phase
N/A
Study Design
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science
Intervention
Name: Met analysis on tissue and blood
Type: Other
Overall Status
Recruiting
Summary
Our project, established through collaboration between clinicians (COL-University Hospital) and scientists (IBL), aims to evaluate the expression of these fragments of Met in the lung cancer (LC). Unlike previous studies on Met by sequencing, in situ hybridization or immunohistochemistry, the investigators propose a protein analysis by Western blotting of tumor samples and healthy tissue. This approach will evaluate the expression of full-length receptor, the presence potential intracellular fragments, and their phosphorylation level.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:

- Patients with non small cell lung cancer (NSCLC)

- Patients candidate for bronchial biopsies on Centre Oscar Lambret (metastatic stage) or candidate for thoracic surgery on CHRU de Lille (localized stage)

- Chemo-naive for metastatic NSCLC

- Patients with or without induction chemotherapy for localized NSCLC

- Male or female subjects ≥ 18 years of age

- Ability to understand and willingness to sign a written Informed Consent

Exclusion Criteria:

- Non malignant tumors

- Small-cell malignancies

- Secondary malignant lesions

- Previous cancer

- Reversal surgery

- Pregnant or breastfeeding women

- Patient under guardianship
Locations
Centre Hospitalier Régional et Universitaire
Lille, France
Status: Not yet recruiting
Contact: Henri PORTE, MDPhD - +33 (0)3.20.44.45.59 - h-porte@chru-lille.fr
Oscar Lambret Center
Lille, France
Status: Recruiting
Contact: Eric DANSIN, MD - +33 (0)3.20.29.59.20 - e-dansin@o-lambret.fr
Start Date
July 2012
Completion Date
July 2015
Sponsors
Centre Oscar Lambret
Source
Centre Oscar Lambret
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page